Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Estrogen-Immune Interface in Endometriosis.

Cells·2025
Same author

Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity.

Seminars in cancer biology·2023
Same author

Adenosine 2A Receptor Activation Amplifies Ibrutinib Antiplatelet Effect; Implications in Chronic Lymphocytic Leukemia.

Cancers·2022
Same author

Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module.

Nature communications·2021
Same author

Dissecting lipid metabolism alterations in SARS-CoV-2.

Progress in lipid research·2021
Same author

Desialylation of <i>O</i>-glycans on glycoprotein Ibα drives receptor signaling and platelet clearance.

Haematologica·2020
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
Same journal

Is low a go for pediatric AML?

Blood·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis
06:03

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis

Published on: July 12, 2011

17.9K

COMP: an endogenous thrombin inhibitor.

Pat Metharom1, Michael C Berndt1

  • 1CURTIN UNIVERSITY.

Blood
|August 15, 2015
PubMed
Summary
This summary is machine-generated.

Cartilage oligomeric matrix protein (COMP) is a key natural inhibitor of thrombin activity. This study shows COMP significantly reduces thrombin

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis
06:03

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis

Published on: July 12, 2011

17.9K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.4K
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

10.5K

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Thrombin is a critical enzyme in blood coagulation.
  • Endogenous inhibitors regulate thrombin activity to prevent thrombosis.
  • The role of cartilage oligomeric matrix protein (COMP) in coagulation is not fully understood.

Purpose of the Study:

  • To investigate the role of cartilage oligomeric matrix protein (COMP) as an endogenous inhibitor of thrombin.
  • To determine the in vitro and in vivo effects of COMP on thrombin activity.

Main Methods:

  • Biochemical assays to measure thrombin inhibition by COMP.
  • In vitro studies using purified proteins and plasma.
  • In vivo studies using animal models of thrombosis.

Main Results:

  • COMP directly inhibits thrombin activity in vitro.
  • Plasma and platelet-derived COMP significantly reduces thrombin generation.
  • COMP administration reduces thrombus formation in vivo.

Conclusions:

  • Cartilage oligomeric matrix protein (COMP) is a major endogenous inhibitor of thrombin.
  • COMP plays a significant role in regulating hemostasis and preventing thrombosis.